Abstract | OBJECTIVES: METHODS: Men and women aged 40 to 75 years with symptomatic osteoarthritis of the knee or hip of at least three months' duration participated in a six week placebo controlled, double blind study with naproxen 500 mg twice daily as one treatment arm. Naproxen was given to 403 patients (280 knee, 123 hip) and placebo to 108 patients (75 knee, 33 hip). WOMAC (Western Ontario and McMaster Universities osteoarthritis index) 3.1 visual analogue scale and SF-36 (36 item short form health survey) were used to assess response to treatment between baseline and week 6. RESULTS: There were no differences at baseline between knee and hip osteoarthritis for any of the WOMAC subscales or SF-36 domains. Improvement was between 4 and 7 mm greater for knee than for hip for all WOMAC subscales ( pain, delta = 4.7 mm (p = 0.03); stiffness, delta = 6.6 mm (p = 0.004); function, delta = 4.8 mm (p = 0.06)). Effect size was about 0.8 for all WOMAC subscales for the knee and between 0.5 and 0.6 for the hip. Knee patients treated with naproxen improved 4.6 (p = 0.033) more than hip patients for SF-36 bodily pain and 10.3 (p = 0.014) more for SF-36 role-physical. CONCLUSIONS:
|
Authors | O Svensson, M Malmenäs, L Fajutrao, E M Roos, L S Lohmander |
Journal | Annals of the rheumatic diseases
(Ann Rheum Dis)
Vol. 65
Issue 6
Pg. 781-4
(Jun 2006)
ISSN: 0003-4967 [Print] England |
PMID | 16269428
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Naproxen
|
Topics |
- Adult
- Aged
- Analysis of Variance
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Double-Blind Method
- Female
- Health Status Indicators
- Humans
- Male
- Middle Aged
- Naproxen
(therapeutic use)
- Osteoarthritis, Hip
(drug therapy)
- Osteoarthritis, Knee
(drug therapy)
- Pain
(drug therapy)
- Pain Measurement
|